In HER2-positive breast cancer patients, intraoperative tumor localization and delineation could be difficult, for example in patients with a residual tumor after neoadjuvant therapy, scheduled for a reoperation or resection of a non-palpable tumor. This evidence concerns the gene ERBB2 and breast cancer.